Antidepressant pharmacotherapy in the treatment of depression in the very old: A randomized, placebo-controlled trial

被引:137
|
作者
Roose, SP
Sackeim, HA
Krishnan, KRR
Pollock, BG
Alexopoulos, G
Lavretsky, H
Katz, IR
Hakkarainen, H
机构
[1] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Radiol, New York, NY 10032 USA
[3] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27706 USA
[4] Univ Pittsburgh, Acad Div Geriatr Psychiat, Pittsburgh, PA 15260 USA
[5] Cornell Univ, Weill Med Coll, Cornell Inst Geriatr Psychiat, White Plains, NY USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Neuropsychiat Inst & Hosp, Los Angeles, CA USA
[7] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[8] Philadelphia VA Med Ctr, Forest Res Inst, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
来源
AMERICAN JOURNAL OF PSYCHIATRY | 2004年 / 161卷 / 11期
关键词
D O I
10.1176/appi.ajp.161.11.2050
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: This study determined the efficacy of antidepressant medication for the treatment of depression in the "old-old." Method: This randomized 8-week medication trial compared citalopram, 10-40 mg/day, to placebo in the treatment of patients 75 and older with unipolar depression. Results: A total of 174 patients who were 58% women with a mean age of 79.6 years (SD=4.4) and a mean baseline Hamilton Depression Rating Scale score of 24.3 (SD=4.1) were randomly assigned to treatment at 15 sites. There was a main effect for site but not for treatment condition. The remission rate, defined as a final Hamilton depression scale score <10, was 35% for the citalopram and 33% for the placebo groups. However, patients with severe depression (baseline Hamilton depression scale score >24) tended to have a higher remission rate with medication than with placebo (35% versus 19%). Conclusions: In the oldest group of community-dwelling patients to be studied to date, medication was not more effective than placebo for the treatment of depression. However, given the considerable psychosocial support received by all patients, the placebo condition represents more than the ingestion of an inactive pill. Across sites, there was considerable range in response to medication, 18% to 82%, and to placebo, 16% to 80%.
引用
收藏
页码:2050 / 2059
页数:10
相关论文
共 50 条
  • [1] Maintenance Treatment of Depression in Old Age A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Combined With Antidepressant Pharmacotherapy
    Reynolds, Charles F., III
    Butters, Meryl A.
    Lopez, Oscar
    Pollock, Bruce G.
    Dew, Mary Amanda
    Mulsant, Benoit H.
    Lenze, Eric J.
    Holm, Margo
    Rogers, Joan C.
    Mazumdar, Sati
    Houck, Patricia R.
    Begley, Amy
    Anderson, Stewart
    Karp, Jordan F.
    Miller, Mark D.
    Whyte, Ellen M.
    Stack, Jacqueline
    Gildengers, Ariel
    Szanto, Katalin
    Bensasi, Salem
    Kaufer, Daniel I.
    Kamboh, M. Ilyas
    DeKosky, Steven T.
    ARCHIVES OF GENERAL PSYCHIATRY, 2011, 68 (01) : 51 - 60
  • [2] Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
    Palhano-Fontes, Fernanda
    Barreto, Dayanna
    Onias, Heloisa
    Andrade, Katia C.
    Novaes, Morgana M.
    Pessoa, Jessica A.
    Mota-Rolim, Sergio A.
    Osorio, Flavia L.
    Sanches, Rafael
    dos Santos, Rafael G.
    Tofoli, Luis Fernando
    Silveira, Gabriela de Oliveira
    Yonamine, Mauricio
    Riba, Jordi
    Santos, Francisco R.
    Silva-Junior, Antonio A.
    Alchieri, Joao C.
    Galvao-Coelho, Nicole L.
    Lobao-Soares, Bruno
    Hallak, Jaime E. C.
    Arcoverde, Emerson
    Maia-de-Oliveira, Joao P.
    Araujo, Draulio B.
    PSYCHOLOGICAL MEDICINE, 2019, 49 (04) : 655 - 663
  • [3] Escitalopram in the Treatment of Adolescent Depression: A Randomized Placebo-Controlled Multisite Trial
    Emslie, Graham J.
    Ventura, Daniel
    Korotzer, Andrew
    Tourkodimitris, Stavros
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2009, 48 (07): : 721 - 729
  • [4] Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial
    Kornstein, Susan G.
    Bose, Anjana
    Li, Dayong
    Saikali, Khalil G.
    Gandhi, Chetan
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (11) : 1767 - 1775
  • [5] DEXAMETHASONE FOR THE TREATMENT OF DEPRESSION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL
    ARANA, GW
    SANTOS, AB
    LARAIA, MT
    MCLEODBRYANT, S
    BEALE, MD
    RAMES, LJ
    ROBERTS, JM
    DIAS, JK
    MOLLOY, M
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (02): : 265 - 267
  • [6] A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents
    Wagner, KD
    Robb, AS
    Findling, RL
    Jin, JQ
    Gutierrez, MM
    Heydorn, WE
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (06): : 1079 - 1083
  • [7] Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial
    Rabkin, JG
    Wagner, GJ
    Rabkin, R
    AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (01): : 101 - 107
  • [8] Scopolamine as a fast-acting antidepressant agent in bipolar depression: a randomized placebo-controlled clinical trial
    Frankel, E.
    Drevets, W.
    Luckenbaugh, D.
    Speer, A.
    Nugent, A.
    Zarate, C.
    Furey, M.
    BIPOLAR DISORDERS, 2011, 13 : 45 - 46
  • [9] Intestinal Microbiota Predict Response to Antidepressant Treatment in a Pilot Randomized Placebo-Controlled Trial of Levomilnacipran in Late-Life Depression
    Lee, Sungeun
    Dong, Tien
    Krause, Beatrix
    Kilpatrick, Lisa
    Siddarth, Prabha
    Lagishetty, Venu
    Jacobs, Jonathan
    Lavretsky, Helen
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 460 - 460
  • [10] A PLACEBO-CONTROLLED TRIAL OF PAROXETINE IN THE TREATMENT OF MAJOR DEPRESSION
    SMITH, WT
    GLAUDIN, V
    JOURNAL OF CLINICAL PSYCHIATRY, 1992, 53 : 36 - 39